Hydrogel composite depot formulation

Inventors

Leino, Lasse • Jalonen, Harry • Forsback, Ari-Pekka • Jokinen, Mika • NOPPARI, Panu

Assignees

DelSiTech Oy

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-10172792-B2

Patent

Publication Date

2019-01-08

Expiration Date


Abstract

This invention relates to a depot formulation comprising a biodegradable silica hydrogel composite incorporating a nucleotide or nucleoside analog reverse transcriptase inhibitor, wherein the silica hydrogel composite is obtainable by mixing silica particles comprising said nucleotide or nucleoside analog reverse transcriptase inhibitor and having a maximum diameter of ≤1 000 μm, as such or as a suspension, with silica sol wherein the hydrogel composite is non-flowing and structurally stable when stored at rest and shear-thinning when shear stress is applied by injection. The present invention also relates to use of the depot formulation for treatment of chronic viral infections and prevention of chronic viral reinfection. The present invention further relates to a prefilled syringes comprising said depot formulation.

Core Innovation

The invention provides a depot formulation comprising a biodegradable silica hydrogel composite incorporating a nucleotide or nucleoside analogue reverse transcriptase inhibitor. The silica hydrogel composite is obtainable by mixing silica particles that comprise the nucleotide or nucleoside analogue reverse transcriptase inhibitor and have a maximum diameter of 1,000 μm or less, as such or as a suspension, with a silica sol.

The silica sol has a solid content of 5 wt-% or less, and the resulting silica hydrogel composite comprises up to 85 wt-% of the silica particles. The hydrogel composite is non-flowing and structurally stable when stored at rest, while being shear-thinning when shear stress is applied by injection.

The described depot formulation is a structurally stable gel at rest that becomes shear-thinning upon injection and remains stable for months, including as a prefilled syringe embodiment with moisture-barrier stability. The formulation is stated for treating chronic viral infections and for preventing chronic viral reinfection, including hepatitis B and HIV indications.

Claims Coverage

The document contains one independent claim defining the overall depot formulation, with dependent claims that further narrow the formulation by adding rheological and mechanical constraints, particle characteristics, inhibitor selection, manufacturing constraints, and device and use embodiments.

Biodegradable silica hydrogel depot with reverse transcriptase inhibitor

A depot formulation comprising a biodegradable silica hydrogel composite incorporating a nucleotide or nucleoside analogue reverse transcriptase inhibitor, wherein the silica hydrogel composite is obtainable by mixing silica particles comprising said inhibitor and having a maximum diameter of 1,000 μm or less, as such or as a suspension, with a silica sol.

Non-flowing and structurally stable at rest with shear-thinning during injection

The silica sol has a solid content of 5 wt-% or less, the silica hydrogel composite comprises up to 85 wt-% of said silica particles, and the hydrogel composite is non-flowing and structurally stable when stored at rest and shear-thinning when shear stress is applied by injection.

Rheology and mechanical threshold definitions for the composite

The depot formulation is characterized by rheological and mechanical constraints including viscosity values within defined ranges at specific shear rates and a complex modulus, measured under small angle oscillatory shear in the linear viscoelastic region, of less than 2400 kPa.

Particle size distribution constraint

The depot formulation is defined with a silica particle size distribution in which the volume fraction of silica particles with diameter less than 1 μm is less than 3 vol-%.

Selected nucleotide or nucleoside analogue reverse transcriptase inhibitor set

The nucleotide or nucleoside analogue reverse transcriptase inhibitor is chosen from zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir, emtricitabine, entecavir, tenofovir, adefovir, apricitabine, elvucitabine, amdoxovir, and racivir.

Continuous incorporation and spray drying with cyclone-separated particle separation

A depot formulation is provided where a nucleotide or nucleoside analogue reverse transcriptase inhibitor is continuously incorporated into silica particles in a tube reactor using separate feed flows of the inhibitor and silica sol, followed by continuous spray drying with particle separation using a cyclone separator.

Overall, the claims cover a biodegradable silica hydrogel composite depot embedding a nucleotide or nucleoside analogue reverse transcriptase inhibitor, with non-flowing structurally stable behavior at rest and shear-thinning upon injection, further constrained by rheology and complex modulus thresholds, particle size distribution limits, defined inhibitor selection, and, within dependent scope, a continuous manufacturing route using tube reactor incorporation and cyclone-separated spray drying.

Stated Advantages

Non-flowing and structurally stable when stored at rest.

Shear-thinning when shear stress is applied by injection.

Improved tolerability as stated in the document via reduced human leukocyte activation and uptake associated with hydrogel embedding and device moisture-barrier performance.

Documented Applications

Treating chronic viral infections, including hepatitis B and HIV indications.

Preventing chronic viral reinfection.

Use in a prefilled syringe embodiment with moisture-barrier stability.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.